EvE Bio Releases Comprehensive Dataset Mapping FDA-Approved Drugs to Cellular Receptors
6.2k words, 29 minutes reading time
Read the full articleYou might also wanna read
MCP and Pharma: How AI Agents Connect to Drug Discovery, Clinical Trials, Genomics, Chemical Databases, Protein Structure, FDA Regulatory Data, and Life Sciences Platforms
A comprehensive guide to MCP integrations for pharmaceuticals, biotechnology, and life sciences — covering drug discovery tools (RDKit, mole
AI Drug Discovery Stalled by Lack of Trustworthy Biological Data
To unleash the potential of AI in life sciences and drug discovery, biological datasets must be authenticated, validated, and supported by s
The Scientist·23d agoAI Drug Discovery Stalled by Lack of Trustworthy Biological Data
To unleash the potential of AI in life sciences and drug discovery, biological datasets must be authenticated, validated, and supported by s
the-scientist.com·23d ago
Global protein-ligand binding affinity profiling via photocatalytic labeling
New approach integrates protein-ligand binding affinity profiling and photocatalytic labeling into a single step, enhancing drug discovery w
Enhancing the Physiological Relevance of Drug Discovery
Elmar Nurmemmedov from CellarisBio discusses real-time and dynamically state-resolved cell target engagement technologies for advancing drug
DrugAgent: Revolutionizing Drug-Target Interaction with AI
DrugAgent uses AI to integrate diverse drug-target interaction data. Evaluated on kinase and antagonist benchmarks, it shows promise for evi
AI-guided discovery identifies GPNMB as promising CAR T cell target for multiple cancers
An AI-guided framework integrating high-resolution cellular atlases, public knowledge databases, and large language models enables a modular
Comments
Sign in to join the conversation.
No comments yet. Be the first.